Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease.
State University of New York at Buffalo, Department of Medicine, VA Upstate New York, 3495 Bailey Avenue, Buffalo, New York 14215, USA.
Nirmal
N
Kaur
Thomas C
TC
Mahl
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D002180:Candidiasis, Oral / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D000069285:Infliximab